Technical Analysis for LENZ - LENZ Therapeutics, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| C | 16.18 | -1.52% | -0.25 |
LENZ closed down 1.52 percent on Wednesday, May 8, 2024, on 1.43 times normal volume. The stock fell below its 50 day moving average, damaging its intermediate-term outlook by crossing under that important trendline. The price action carved out a bullish hammer (or hammer-like) candlestick pattern. That may indicate an upside reversal. Look for price to trade above the high of the hammer for confirmation.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Up | Down | Flat |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Fell Below 50 DMA | Bearish | 0.00% | |
| Hammer Candlestick | Bullish | 0.00% | |
| Earnings Movers | Other | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| 50 DMA Support | Bullish | -1.52% | |
| NR7 | Range Contraction | -1.52% | |
| Narrow Range Bar | Range Contraction | -1.52% | |
| Wide Bands | Range Expansion | -1.52% | |
| 50 DMA Support | Bullish | 0.00% | |
| Wide Bands | Range Expansion | 0.00% |
| Alert | Time |
|---|---|
| Down 3% | about 14 hours ago |
| Fell Below Previous Day's Low | about 14 hours ago |
| 60 Minute Opening Range Breakdown | about 14 hours ago |
| Fell Below 10 DMA | about 14 hours ago |
| 10 DMA Support | about 15 hours ago |
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/08/2024
LENZ is a late clinical-stage biopharmaceutical company focused on developing the first aceclidine-based eye drop to improve vision in patients diagnosed with presbyopia. LENZ’s product candidates, LNZ100 and LNZ101, are preservative-free, single-use, once-daily eye drops containing aceclidine and aceclidine plus brimonidine, respectively. LNZ100 and LNZ101 are under clinical evaluation in the registration-enabling Phase 3 CLARITY trials as potential therapies for the treatment of presbyopia, a condition impacting an estimated 1.8 billion people globally and 128 million people in the United States. LENZ is committed to commercializing an ideal pharmaceutical presbyopia solution that enhances vision for "all eyes, all day." LENZ is headquartered in San Diego, California.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Presbyopia
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Presbyopia
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 24.59 |
| 52 Week Low | 6.6976 |
| Average Volume | 127,243 |
| 200-Day Moving Average | 10.34 |
| 50-Day Moving Average | 16.26 |
| 20-Day Moving Average | 17.19 |
| 10-Day Moving Average | 16.10 |
| Average True Range | 1.16 |
| RSI (14) | 42.20 |
| ADX | 25.56 |
| +DI | 21.32 |
| -DI | 18.89 |
| Chandelier Exit (Long, 3 ATRs) | 18.59 |
| Chandelier Exit (Short, 3 ATRs) | 18.61 |
| Upper Bollinger Bands | 21.21 |
| Lower Bollinger Band | 13.18 |
| Percent B (%b) | 0.37 |
| BandWidth | 46.70 |
| MACD Line | -0.31 |
| MACD Signal Line | -0.14 |
| MACD Histogram | -0.177 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 17.10 | ||||
| Resistance 3 (R3) | 17.03 | 16.67 | 16.94 | ||
| Resistance 2 (R2) | 16.67 | 16.43 | 16.70 | 16.89 | |
| Resistance 1 (R1) | 16.42 | 16.29 | 16.24 | 16.49 | 16.84 |
| Pivot Point | 16.06 | 16.06 | 15.96 | 16.09 | 16.06 |
| Support 1 (S1) | 15.81 | 15.82 | 15.63 | 15.87 | 15.52 |
| Support 2 (S2) | 15.45 | 15.68 | 15.48 | 15.47 | |
| Support 3 (S3) | 15.20 | 15.45 | 15.42 | ||
| Support 4 (S4) | 15.26 |
